Canaccord Genuity Downgrades Exactech Inc (EXAC) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St set to open lower after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
Exactech Q1 Revenue $61.4 Million. Net Income Down 2% to $4.1 Million. Diluted EPS $0.29 vs. $0.30.
April 28, 2015 4:01 PM EDTGAINESVILLE, Fla.--(BUSINESS WIRE)-- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today revenue of $61.4 million for the first quarter of 2015, a 3% decrease from $63.3 million in the first quarter of 2014. On a constant currency basis, revenue was flat. Net income was $4.1 million, or $0.29 per diluted share, compared to $4.2 million, or $0.30 per diluted share, in the same quarter a year ago.
First Quarter Segment Performance
The first quarter of 2015 was significantly impacted... More



